HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Wednesday, MarketBeat.com reports. They presently have a $39.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 16.94% from the stock’s current price. HC Wainwright also issued estimates for Genmab A/S’s FY2025 earnings at $2.00 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.49 EPS and Q3 2026 earnings at $0.47 EPS.

Several other research firms have also commented on GMAB. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Finally, Truist Financial restated a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.25.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $33.35 on Wednesday. The stock has a 50 day moving average price of $32.42 and a 200-day moving average price of $28.97. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The company has a market capitalization of $21.42 billion, a P/E ratio of 14.19, a P/E/G ratio of 18.54 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $975.40 million. As a group, equities analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of the business. Alliancebernstein L.P. increased its stake in Genmab A/S by 2.7% in the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock worth $335,957,000 after purchasing an additional 291,538 shares during the period. Orbis Allan Gray Ltd boosted its stake in shares of Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares during the period. Paradigm Biocapital Advisors LP bought a new position in shares of Genmab A/S in the third quarter worth about $117,063,000. Arrowstreet Capital Limited Partnership increased its stake in Genmab A/S by 5.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock worth $111,735,000 after buying an additional 188,761 shares during the period. Finally, First Trust Advisors LP lifted its holdings in Genmab A/S by 3.5% during the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock valued at $36,575,000 after buying an additional 60,504 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 price target on GMAB, implying roughly mid-teens upside from current levels — supportive of investor demand. H.C. Wainwright Reiterates Buy Rating on Genmab AS (GMAB)
• Positive Sentiment: HC Wainwright raised its FY2025 EPS projection to $2.00 (from $1.89), signaling higher expected full-year profitability that can support valuation. HC Wainwright / Marketbeat
• Neutral Sentiment: Genmab granted 32,806 restricted stock units and 34,307 warrants to employees. The award is standard compensation-related dilution but is very small relative to the company’s outstanding shares, so impact is likely minimal. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short-interest data for January appear anomalous (showing 0 shares / NaN change) and are inconclusive — not a reliable signal of bearish pressure at this time.
• Negative Sentiment: HC Wainwright cut near-term quarterly EPS forecasts (Q1 → $0.27 from $0.34; Q2 → $0.49 from $0.58; Q3 → $0.47 from $0.59), which reduces near-term earnings expectations and could weigh on sentiment if investors focus on short-term performance. HC Wainwright / Marketbeat

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.